City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Leslie Popplewell, MD  
Search results:  5  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-5 Trials Jump to page:

COH Protocol Number: 15310 ClinicalTrials.gov Number: NCT02260804

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphoma

COH Protocol Number: 15182 ClinicalTrials.gov Number: NCT02413489

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

COH Protocol Number: 14011 ClinicalTrials.gov Number: NCT02142049

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Multicenter Study of Ibrutinib and Lenalidomide in Combination with DA-EPOCH-R in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma

COH Protocol Number: 13277 ClinicalTrials.gov Number: NCT02051257

Principal Investigator: Leslie Popplewell, MD
Sponsor: NCI Approved External Peer Review

Title:  Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

COH Protocol Number: 12260 ClinicalTrials.gov Number: NCT01729806

Principal Investigator: Leslie Popplewell, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-69, NCI #9197: A Phase I study of Ipilimumab in Combination with Rituximab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma

 
Results per page: 25 50 100 All 1-5 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.